EICHOR
● Active Not Recruiting
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Hematological Malignancies · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (51)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| City of Hope | Duarte, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| Winship Cancer Institute Emory University | Atlanta, Georgia, United States | — |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects | New York, New York, United States | — |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | — |
| Levine Cancer Institute | Charlotte, North Carolina, United States | — |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
| Universitair Ziekenhuis Gent - UZ GENT | Ghent, Belgium | — |
| Universitaire Ziekenhuizen Leuven | Leuven, Belgium | — |
+ 39 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.